ABL1 and diabetes mellitus: Other classical imatinib TK targets, such as c-Kit and the PDGF receptor, have received less attention than c-Abl when it comes to protection against beta-cell death and diabetes, but one report states that c-Kit is not necessary for imatinib-induced protection against diabetes in NOD mice (8).